Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Justin S. Waters"'
Autor:
Daniel Catovsky, Matthew C.H. Ng, A C Wotherspoon, David Cunningham, Mark A. Hill, Alan Horwich, Ian Chau, A. R. Norman, Justin S. Waters
Publikováno v:
British Journal of Cancer
There is currently no standard salvage chemotherapy regimen in relapsed and refractory lymphoma. Gemcitabine is a novel nucleoside analogue, which acts synergistically with cisplatin both in vitro and in clinical studies. We evaluated the combination
Autor:
Roger A'Hern, Tim Eisen, M. G. James, S Hackett, Justin S. Waters, Martin Gore, C Moss, Lynda Pyle
Publikováno v:
British Journal of Cancer
We report a single institution phase II study of gemcitabine 1200 mg m(-2) i.v. on days 1 and 8 and capecitabine 1300 mg m(-2) twice daily on days 1-14 of each 3-week cycle in patients with metastatic renal carcinoma. Patients had a WHO performance s
Autor:
M.E. Hill, Justin S. Waters, A. R. Norman, Gina Brown, Jacqui Oates, David Cunningham, L. Assersohn, C. Ward
Publikováno v:
Annals of Oncology. 15:64-69
Phase II study of irinotecan and 5-fluorouracil/leucovorin in patients with primary refractory or relapsed advanced oesophageal and gastric carcinoma Background: The purpose of this study was to assess the efficacy and toxicity of irinotecan and 5-fl
Publikováno v:
British Journal of Cancer
The purpose of this study was to evaluate the activity and safety of oxaliplatin and protracted venous infusion of 5-fluorouracil (PVI 5-FU) in patients with advanced or relapsed 5-FU pretreated colorectal cancer. 38 patients with advanced or metasta
Autor:
Ian Chau, Mark A. Hill, Gary Middleton, P J Ross, Jacqui Oates, C. Topham, R Katopodis, A. R. Norman, Justin S. Waters, G. Stewart, David Cunningham
Publikováno v:
British Journal of Cancer
Elderly patients are recommended to have a reduced starting dose (300 mg m(-2) once every 3 weeks) of irinotecan monotherapy. The aims of this analysis are to compare toxicity and survival according to age, performance status (PS), gender and prior r